A patient is recovering after an acute noncardioembolic ischemic stroke and is receiving standard antiplatelet therapy. You are considering evidence for adding a factor XIa inhibitor to reduce recurrent ischemic events.
Which conclusion is supported by this systematic review and meta-analysis?
